ACTU Actuate Therapeutics Inc. Operating Sales Margin

Public company logo of Actuate Therapeutics Inc. (ACTU)

Actuate Therapeutics, Inc. (ACTU) is developing advanced targeted therapies to combat resistant forms of cancer, leveraging attracted investments. The operating margin metric demonstrates the current efficiency of this model, where the parameter value equals 0.00. Patents for kinase inhibitors and stringent FDA oversight ensure a high barrier to entry. However, the early stage of testing and reliance on speculative capital create critical financial risks.

ACTU: Actuate Therapeutics Inc. Operating Return on Sales 08/14/2024 - 11/20/2026

Financial and market metric breakdowns for Actuate Therapeutics, Inc. (ACTU)

- share price and consensus valuation forecast:
Fundamental company valuation:actuatetherapeutics.com, ACTU
Brand item of Actuate Therapeutics Inc

Operating margin measures cost management efficiency by determining the share of profit from core operations relative to total revenue. This indicator assesses a business's ability to generate cash flow before accounting for debt obligations and taxes. For Actuate Therapeutics, Inc. (ACTU), which is developing methods to combat advanced cancer, this metric reflects the cost of innovative research and development. By analyzing operating margins, an investor can track the transformation of scientific achievements into economic results. The stability of this figure confirms the fundamental resilience of the biotech startup.

Competitors of Actuate Therapeutics, Inc.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin